Introduction

Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are among the most debilitating neurodegenerative disorders affecting millions of people worldwide. Together with Parkinson’s disease dementia (PDD), they form the spectrum of Lewy body diseases (LBDs) — conditions unified by a shared neuropathological hallmark: the progressive accumulation of misfolded alpha-synuclein (α-syn) protein within neurons.

Despite decades of research, both conditions remain difficult to diagnose accurately — particularly in their early stages. Up to 40% of patients clinically diagnosed with early Parkinson’s disease may not actually have PD, and Lewy body dementia is frequently misidentified as Alzheimer’s disease (AD), leading to inappropriate treatments and delayed care. The urgent need for objective, reliable biological markers has made alpha-synuclein biomarkers one of the most active frontiers in neurology.

This article provides a comprehensive overview of the current state of alpha-synuclein as a biomarker across multiple biological matrices — from cerebrospinal fluid and blood plasma to skin and olfactory tissue — along with the emerging technologies driving this field forward.

What Is Alpha-Synuclein and Why Does It Matter?

Alpha-synuclein (α-syn) is a small, 14-kilodalton presynaptic neuronal protein encoded by the SNCA gene. Under normal conditions, it plays roles in modulating synaptic vesicle stability and neurotransmitter release. However, in certain pathological states, α-syn undergoes misfolding — shifting from its normal helical conformation into β-sheet-rich aggregates that resist breakdown.

These misfolded aggregates accumulate into characteristic structures called Lewy bodies and Lewy neurites, which are the neuropathological signatures of Parkinson’s disease, dementia with Lewy bodies, and Parkinson’s disease dementia. In multiple system atrophy (MSA), a related condition, similar misfolded α-syn accumulates in glial cytoplasmic inclusions rather than neurons.

Mutations and multiplications of the SNCA gene are directly linked to familial forms of Parkinson’s disease, and genome-wide association studies (GWAS) have identified SNCA variants as significant risk factors for sporadic PD as well. This central role in disease pathogenesis makes α-syn a logical, compelling biomarker candidate — if it can be reliably detected in accessible biological samples.

The Diagnostic Challenge: Why Better Biomarkers Are Needed

Parkinson’s Disease

Parkinson’s disease affects more than 1% of the global population over the age of 65 and is the second most common neurodegenerative disorder after Alzheimer’s disease. Its diagnosis relies heavily on clinical assessment — evaluating symptoms like bradykinesia, rigidity, resting tremor, and postural instability — supplemented by dopamine transporter (DAT) PET imaging.

While experienced movement disorder specialists can achieve high diagnostic accuracy at advanced disease stages, early-stage diagnosis remains unreliable. Nearly one-third of clinical diagnoses in patients with parkinsonism are revised within the first five years, and DAT imaging lacks specificity for synucleinopathies specifically, since it shows similar findings in atypical Parkinsonism including MSA and DLB.

Dementia with Lewy Bodies

DLB is the second most common cause of degenerative dementia after Alzheimer’s disease, yet it is chronically underdiagnosed. Its clinical features — including fluctuating cognition, visual hallucinations, Parkinsonism, and REM sleep behavior disorder (RBD) — overlap substantially with Alzheimer’s disease. Moreover, Alzheimer’s co-pathology is present in approximately 70% of DLB patients at autopsy. The stakes of misdiagnosis are high: patients with DLB can have severe adverse reactions to antipsychotic medications commonly used in Alzheimer’s care.

Alpha-Synuclein Biomarkers: Biological Matrices

Alpha-synuclein seeds — the nucleating, aggregation-competent forms of the protein — are distributed not only in the brain but throughout the body, including the peripheral autonomic nervous system. This systemic distribution opens the possibility of detecting disease pathology from multiple, sometimes minimally invasive, biological sources.

1. Cerebrospinal Fluid (CSF)

Cerebrospinal fluid has historically been the most studied matrix for α-syn biomarkers, given its proximity to the central nervous system. Early research focused on measuring total α-syn levels in CSF using enzyme-linked immunosorbent assay (ELISA), finding that CSF α-syn is generally reduced in Parkinson’s disease compared to controls — a counterintuitive finding explained by neuronal loss and sequestration of the protein into aggregates.

Studies also suggested that measuring CSF α-syn alongside tau protein could help distinguish synucleinopathies from other neurodegenerative disorders. However, measuring total α-syn concentrations proved insufficient for high diagnostic accuracy, largely because neither monomeric nor total protein levels reliably distinguish between disease subtypes. The pivotal advance came with the development of seed amplification assays (SAAs).

Seed Amplification Assays: A Paradigm Shift

Seed amplification assays represent the most significant breakthrough in α-syn biomarker science in recent years. The two principal methods are real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA). Both work on the same principle: patient-derived biological samples are incubated with recombinant monomeric α-syn. If even tiny amounts of misfolded “seeds” are present, they catalyze the aggregation of the recombinant protein, producing a measurable fluorescent signal.

The diagnostic accuracy of CSF α-syn SAAs is remarkable. The commercially available SAAmplify™–αSYN test, offered through Mayo Clinic Laboratories, reports 96% sensitivity and 92% specificity in detecting α-synuclein pathology — making it the first commercially available SAA for synucleinopathies in the United States. The test is indicated for patients with clinically uncertain cognitive decline or Parkinsonian syndromes.

A 2025 review in Alzheimer’s & Dementia confirmed that CSF and skin α-syn SAAs are highly accurate diagnostic biomarkers for DLB versus AD, with particularly high specificity. SAA positivity was strongly associated with key clinical features of DLB, including parkinsonism, REM sleep behavior disorder, fluctuating cognition, and hyposmia.

Beyond CSF: Expanding the Biomarker Toolkit

Despite the promise of CSF-based assays, lumbar puncture is invasive, uncomfortable, and poorly suited to widespread clinical use or repeated longitudinal monitoring. This has driven intensive research into less invasive biological sources.

2. Skin Biopsy

Perhaps the most promising minimally invasive approach involves detecting phosphorylated α-syn (pS129) in cutaneous nerve fibers through skin punch biopsy. Alpha-synuclein aggregates are present not only in brain neurons but in peripheral autonomic nerves, including those innervating the skin. A landmark 2024 study in JAMA by Gibbons et al. demonstrated high diagnostic accuracy for synucleinopathies using immunohistochemical detection of pS129-α-syn in skin. Skin-based RT-QuIC assays have also shown strong performance in distinguishing DLB from AD, though technical standardization and larger validation cohorts are still needed.

3. Blood and Plasma

Blood-based biomarkers represent the holy grail of neurodegenerative diagnostics — accessible, scalable, and suitable for repeated testing. However, α-syn in blood is complicated by the fact that most circulating α-syn originates from red blood cells (erythrocytes) rather than neurons, creating a noisy background that can obscure pathological signals. Despite these challenges, several promising approaches have emerged:

• Plasma total and phosphorylated α-syn: A longitudinal study in Scientific Reports found that plasma total α-syn levels increase progressively with disease duration in PD, while phosphorylated α-syn at Ser-129 may have value as a diagnostic marker.
• Aggregated α-syn in red blood cells: A 2025 study found that aggregated α-syn measurable in erythrocytes using a fibrillar/oligomeric-selective ELISA could discriminate Parkinson’s disease patients from age- and sex-matched controls.
• Plasma SAAs (CSIC assay): A 2025 study in npj Parkinson’s Disease described the Constant Shake-Induced Conversion (CSIC) assay for detecting α-syn aggregates directly in plasma. In 102 participants, it achieved an AUC of 0.91, with 81% sensitivity and 85% specificity.
• Alpha-synuclein strains in plasma: A landmark 2025 Annals of Neurology study (Kannarkat et al.) used monoclonal antibodies selective for two α-syn conformational “strains” to evaluate brain tissue, CSF, and plasma. They found that circulating plasma α-syn strains differ between PD and DLB, opening the possibility of blood tests that distinguish these conditions — something no existing biomarker does reliably.

4. Olfactory Mucosa

Loss of smell (hyposmia) is a well-established prodromal symptom of PD and DLB, preceding motor symptoms by years. Alpha-synuclein pathology in the olfactory system has been detected using SAAs applied to olfactory mucosa obtained through nasal brushings — a minimally invasive procedure. Studies have shown detectable α-syn seeding activity in olfactory mucosa from PD and DLB patients, making this an intriguing candidate for early detection workflows.

5. Extracellular Vesicles and Exosomes

Neurons package and release α-syn in extracellular vesicles (EVs) and exosomes — nanoparticles that can be isolated from plasma or CSF. Neuronally-derived exosomal α-syn has shown diagnostic sensitivity and specificity comparable to CSF α-syn, while being obtainable from a peripheral blood draw. A 2024 study in JAMA Neurology found that neuronally-derived EV α-syn in serum could identify individuals at risk for developing Parkinson’s disease.

Two-Step Diagnostic Workflows

Given the cost and invasiveness of CSF testing, researchers are exploring intelligent screening strategies. A notable 2025 study in Nature Communications evaluated a two-step workflow combining olfactory prescreening (smell-function testing) with confirmatory CSF α-syn SAA only in individuals with reduced smell. Among 358 autopsied participants, this workflow predicted Lewy body pathology with 94% overall accuracy while reducing the need for CSF testing by 43%. In clinically unimpaired individuals, it reduced CSF testing requirements by 80% — dramatically reducing patient burden and healthcare costs while maintaining high diagnostic accuracy.

Distinguishing PD from DLB: The Next Frontier

One of the most pressing unmet needs in the field is a biomarker capable of distinguishing Parkinson’s disease from dementia with Lewy bodies — two conditions that share α-syn pathology but differ substantially in their clinical course, cognitive profiles, and treatment implications. Current SAAs confirm the presence of synuclein pathology but cannot reliably differentiate between LBD subtypes. The 2025 work by Kannarkat et al. using strain-selective antibodies represents the most promising step toward this goal, suggesting that the conformational properties of circulating α-syn species differ between PD and DLB.

New Diagnostic Frameworks: SynNeurGe and Biological Staging

The field is moving beyond purely clinical definitions toward biologically-defined disease classification. In 2024, two landmark papers in The Lancet Neurology proposed new frameworks:

• SynNeurGe criteria (Höglinger et al.) classify Parkinson’s disease based on three biological pillars: Synuclein pathology (S), Neuronal dysfunction (N), and Genetic risk (Ge).
• Integrated biological staging (Simuni et al.) proposed a staging system for neuronal α-syn disease. Both frameworks rely critically on α-syn biomarkers as foundational diagnostic evidence, underscoring how central these tests are becoming to the future of PD and LBD diagnosis and clinical trial design.

Clinical Availability and Limitations

As of 2025, the SAAmplify™–αSYN CSF assay from Mayo Clinic Laboratories represents the only commercially available SAA for synucleinopathies in the United States. Key limitations of the current biomarker landscape include:

• Standardization: Different laboratories use different SAA protocols, making cross-study comparisons difficult.
• DLB co-pathology: Up to 70% of DLB patients have concurrent Alzheimer’s pathology, complicating interpretation of combined biomarker panels.
• Prodromal detection: Most validated data comes from patients with established disease. Performance in truly prodromal or at-risk individuals requires further study.
• Differentiation between synucleinopathies: Current assays cannot reliably distinguish PD from DLB from MSA, though strain-based approaches may address this.
• Blood-based assay standardization: Plasma and serum assays are still predominantly in the research phase and require rigorous clinical validation.

Future Directions

The next five years are likely to see:

• Validated blood-based α-syn tests entering clinical practice, democratizing access to synuclein diagnostics without lumbar puncture.
• Multi-biomarker panels combining α-syn SAA with Alzheimer’s biomarkers (amyloid, tau), genetic markers, and neuroimaging for comprehensive, biologically precise diagnosis.
• Strain-discriminating assays capable of differentiating PD from DLB and MSA.
• Longitudinal monitoring tools using plasma or urine α-syn to track disease progression and assess therapeutic response in clinical trials.
• Prodromal screening programs using two-step workflows in at-risk populations (RBD patients, first-degree relatives of PD patients, those with hyposmia).

Conclusion

Alpha-synuclein biomarkers are transforming the diagnosis and understanding of Parkinson’s disease and Lewy body dementia. From highly accurate CSF seed amplification assays already available commercially to emerging blood-based and minimally invasive approaches, the toolkit is expanding rapidly. The shift toward biologically-defined disease classification — anchored by α-syn biomarker status — promises earlier diagnosis, more precise clinical trial enrollment, and ultimately, better outcomes for the millions of people living with these devastating conditions.

As the field moves from bench to bedside, the integration of α-syn biomarkers into routine clinical care represents not just a scientific achievement, but a profound step forward in the compassionate care of patients and families affected by synucleinopathies.

References

1. Kannarkat GT, Zack R, Skrinak RT, et al. Blood α-Synuclein Separates Parkinson’s Disease from Dementia with Lewy Bodies. Ann Neurol. 2025;98(4):682–698. https://pubmed.ncbi.nlm.nih.gov/40521808/
2. McWilliam O, et al. α-Synuclein seed amplification assay in Lewy body dementia versus Alzheimer’s disease. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2025. https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/dad2.70203
3. Mammana A, et al. Alpha-synuclein seeding amplification assays in Lewy body dementia: a brief review. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12210522/
4. Coughlin DG, et al. CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies. Neurology. 2025. https://www.neurology.org/doi/10.1212/WNL.0000000000214346
5. Mayo Clinic Laboratories. Synucleinopathies: Dementia with Lewy bodies, Parkinson’s, and multiple system atrophy. https://news.mayocliniclabs.com/neurology/dementia/synucleinopathies/
6. Kang UN, et al. Alpha-synuclein seed amplification assay positivity beyond synucleinopathies. eBioMedicine. 2025. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00369-X/fulltext
7. Li H, et al. Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification. Nature Communications. 2025. https://www.nature.com/articles/s41467-025-62458-7
8. Rissardo JP, et al. α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders. Journal of Movement Disorders. 2024. https://www.e-jmd.org/journal/view.php?doi=10.14802/jmd.24075
9. Miranda C, et al. Alpha-Synuclein Seed Amplification Assays in Parkinson’s Disease: A Systematic Review. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12192484/
10. Novel CSIC Plasma Assay for Parkinson’s Disease Diagnosis. npj Parkinson’s Disease. 2025. https://www.nature.com/articles/s41531-025-01083-z
11. Jeong JY, Kim N, Li Y, et al. Elevated plasma levels of alpha-synuclein are dispensable for Parkinson’s disease pathology. npj Parkinson’s Disease. 2025. https://www.nature.com/articles/s41531-025-01091-z
12. Foulds PG, et al. A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson’s disease. Scientific Reports. 2013. https://www.nature.com/articles/srep02540
13. Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson’s Disease. Frontiers in Neurology. 2019. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.01388/full
14. Gibbons CH, et al. Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA. 2024;331:1298–1306. https://jamanetwork.com/journals/jama/article-abstract/2816918
15. Höglinger GU, et al. A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria. Lancet Neurology. 2024;23:191–204. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00402-X/abstract
16. Simuni T, et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurology. 2024;23:178–190. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00405-5/abstract
17. Aggregated α-synuclein in erythrocytes as a potential biomarker for idiopathic Parkinson’s Disease. ScienceDirect. 2025. https://www.sciencedirect.com/science/article/pii/S1353802025000628